Clinical Benefit Rate (CBR) is defined as the percentage of advanced cancer patients who achieve complete remission, partial remission, or at least six months of stable disease after treatment. Some argue that CBR should not be used at all, because it does not measure clinical benefit. However, its use is also supported as, like DCR, CBR can be used to quickly assess the anti-cancer activity and can further capture the stability of the disease.